Abstract: Successful treatment of narcolepsy requires an accurate diagnosis to exclude patients with other sleep disorders, which have different treatments, and to avoid unnecessary complications of drug treatment. Treatment objectives should be tailored to individual circumstances. Modafinil, amphetamine, methamphetamine, dextroamphetamine, methylphenidate, selegiline, pemoline, tricyclic antidepressants, and fluoxetine are effective treatments for narcolepsy, but the quality of published clinical evidence supporting them varies. Scheduled naps can be beneficial to combat sleepiness, but naps seldom suffice as primary therapy. Regular follow up of patients with narcolepsy is necessary to educate patients and their families, monitor for complications of therapy and emergent of other sleep disorders, and help the patient adapt to the disease.
INTRODUCTION

NARCOLEPSY IS CHARACTERIZED BY UNCONTROL-LABLE SLEEPINESS (ALSO CALLED EXCESSIVE DAY-TIME SLEEPINESS) AND INTERMITTENT MANIFESTA-TIONS OF REM SLEEP AT TIMES WHEN A PERSON
WOULD NORMALLY BE AWAKE. Beside sleepiness, the REM manifestations may include cataplexy, sleep paralysis, and hypnagogic hallucinations. Narcolepsy is not a common disease. The largest population study estimates the prevalence of narcolepsy at 26 per 100,000 people in Finland, which is similar to the prevalence of myasthenia gravis, Marfan's syndrome, systemic lupus erythematosis, and Crohn's disease. The actual prevalence may be higher in the United States, 1 where approximately 5% of patients seen at AASM accredited sleep disorder centers have narcolepsy. 2 Narcolepsy has clinical importance which exceeds its prevalence. A lifelong, often disabling, condition such as narcolepsy demands that many health care providers besides sleep specialists must be familiar with optimum treatments. Sleep attacks associated with narcolepsy can lead to serious accidents or loss of employment, so treatment to reduce excessive sleepiness has clinical and societal value. Nevertheless, many health care providers are overly cautious in approaching treatment of narcolepsy, because stimulant medications, which are the mainstay of narcolepsy treatment, are regulated by government agencies to prevent abuse.
Because of the importance of narcolepsy treatment, the American Academy of Sleep Medicine (AASM) sponsored a review paper on the use of stimulants for treatment of narcolepsy in 1994. 3 Based on that review, the Standards of Practice Committee (SPC) of the AASM published practice parameters on narcolepsy therapy with stimulants 4 Since publication of the initial review and practice parameters several developments have occurred. Researchers have identified a potential biochemical basis of narcolepsy in dogs and humans. 5, 6 The genetic defect in canine narcolepsy associated with cataplexy results in a nonfunctional receptor (OX2R) for hypocretin (orexin), a neurotransmitter previously associated with feeding behavior and energy metabolism. In humans, hypocretin is reduced or undetectable in many but not all patients with narcolepsy associated with cataplexy. Also, the United States Food and Drug Administration (FDA) approved modafinil for treatment of narcolepsy. There is optimism that these research and clinical developments will result in better treatment and quality of life for patients with narcolepsy.
In 1999, the Agency for Healthcare Research and Quality in partnership with the American Medical Association (AMA) and the American Association of Healthplans, established the National Guideline Clearinghouse™ (NGC), a comprehensive database of evidence-based clinical practice guidelines and related documents. The clearinghouse provides a central repository of practice parameters from all medical specialties. To be listed, practice parameters must have been developed, reviewed, or revised every five years and must be based on a systematic review of scientific evidence published in peer-reviewed journals. 7 In view of the new treatments, basic research advances, and the NGC protocol, the AASM decided to update the practice parameters for treatment of narcolepsy. This update concerns advances in therapy for narcolepsy since the publication of the expert review; 3 grades the evidence available; and modifies and replaces the1994 practice parameters.
METHODS
The SPC examined the published practice parameters and the review upon which they were based. 3, 4 The references cited in Table 1 of the 1994 review paper were included in this reassessment, unless they were conference abstracts or letters to the editor. 3 Medline was searched from 1993 through and including articles published up to August 2000 with subject headings narcolepsy or cataplexy. In addition, human clinical trials, Americans with Disabilities Act, quality of life, driving, and compliance each were used as limiting terms. Finally, pemoline and methylphenidate were used as subject headings to discover information about toxic side effects. For information about teratogenicity, a textbook 8 about prescription medication use in pregnancy was employed and the medication graded according to the FDA system as described in the Physicians' Desk Reference, 2000 edition. Case reports, abstracts, editorials, letters, and reviews were excluded except for reports of adverse effects of treatments. All clinical trials of therapy were considered for the evidence tables. Case series and database articles about diagnosis of narcolepsy were incorporated in the evidence tables only if they included greater than 20 subjects. Examination of the reference lists from the articles found in the Medline search provided a few relevant studies from literature published prior to 1993. Evidence from the 1994 review and the updated Medline search was rated for the studies according to the classification outlined in Table 1 .
For an economic indicator about drug costs, the wholesale price, as listed in the Drug Topics Red Book Update was used. 10 This is the current benchmark for drug price information.
The Board of Directors of the American Academy of Sleep Medicine reviewed the SPC for material conflicts of interest relevant to the recommendations and approved the final version of the parameters prior to publication.
On the basis of this review, the SPC of the American Academy of Sleep Medicine rated the recommendations of this paper as standards, guidelines, and options (Table 2 ), based on evidence from studies published in peer-reviewed journals that were evaluated as noted in the evidence tables (Tables 3 and 4) . However, when scientific data are absent, insufficient, or inconclusive, the recommendations were based on consensus opinion. Each recommendation is based on the level and grade of the evidence available, or on consensus when evidence is lacking.
These practice parameters define principles of practice that should meet the needs of most patients in most situations. These guidelines should not, however, be considered inclusive of all proper methods of care or exclusive of other methods of care reasonably directed toward obtaining the same results. The ultimate judgment regarding the propriety of any specific care must be made by health care providers in light of the individual circumstances presented by the patient and the available diagnostic and treatment options as resources.
The American Academy of Sleep Medicine expects these guidelines to have a positive impact on professional behavior, patient outcomes, and, possibly, health care costs. These practice parameters reflect the state of knowledge at the time of development and will be reviewed, updated, and revised, as new information becomes available.
RESULTS
The Medline search for narcolepsy and clinical trials yielded 29 articles, of which 14 were relevant to this paper. The Medline search of narcolepsy and human returned 450 articles. In the narcolepsy and human search, several clinical trials were found which did not show up in the more limited search. The Medline search for narcolepsy and compliance yielded one relevant article. The search for narcolepsy and driving yielded 26 references, of which six proved relevant. Narcolepsy and quality of life yielded 15 references of which three proved to contain original Adapted from Sackett 9 *Alpha error refers to the probability (generally set at 95% or greater) that a significant result (e.g., p<0.05) is the correct conclusion of the study or studies. Beta error refers to the probability (generally set at 80% or 90% or greater) that a nonsignificant result (e.g., p>0.05) is the correct conclusion of the study or studies. The estimation of beta error is generally the result of a power analysis. The power analysis includes a sample size analysis which projects the size of the study population necessary to ensure that significant differences will be observed if actually present. data. Other articles about quality of life in narcolepsy were found in the reference sections of these articles. Although the search under Americans with Disabilities Act yielded 469 references, none were directly related to narcolepsy. The search under cataplexy yielded 169 articles, of which 36 were human clinical studies, but many turned out to be case reports or small case series. Tables 3 and 4 list most of the citations on which the updated practice parameters are based.
Recommendations
Recommendations that are similar to, or an expansion of, previous ones and new recommendations are noted as such in the text.
1.
An accurate diagnosis of narcolepsy should be established which shall include a thorough evaluation of other possible contributing causes, apart from narcolepsy, to the excessive daytime sleepiness {Standard}.
For patients suspected of having narcolepsy, an all-night polysomnogram is done primarily to ascertain the presence of concurrent sleep disorders and is followed immediately by a multiple sleep latency test 50, 51 (MSLT) to help confirm the diagnosis. The MSLT also helps determine the severity of daytime sleepiness. The reader is referred for diagnostic criteria [33] [34] [35] 50 (Table 4) . Other methods to evaluate sleepiness include objective tests such as the maintenance of wakefulness test 51 (MWT), and subjective approaches such as the Epworth Sleepiness Scale. 52 This part of the recommendation is based on committee consensus and is similar to a recommendation made previously. 4 Chronic daytime sleepiness is a nonspecific symptom and conditions that produce such sleepiness may coexist with narcolepsy. For example, the obstructive sleep apnea syndrome (OSAS) and periodic limb movement disorder (PLMD) may be present as determined by the results of the all-night polysomnogram. Insufficient sleep, idiopathic hypersomnia, inadequate sleep hygiene, and circadian rhythm disorders, among others should be considered as possible contributors to sleepiness independent of narcolepsy. 50 Management of other disorders possibly contributing to sleepiness in a patient with narcolepsy may require approaches apart from stimulants to treat sleepiness either directly or as therapy of the underlying condition. This part of the recommendation is new and is based on committee consensus.
2.
Individual treatment objectives should be established for each patient with narcolepsy to improve quality of life {Standard}. One level II, grade B, four level III, grade C, and one level V, grade C, studies, and committee consensus, provide evidence that symptoms of narcolepsy may adversely impact quality of life 18, [36] [37] [38] [39] [40] [41] (Tables 3 and 4 ). In keeping with the previous practice parameters, 4 a major objective of treatment should be to alleviate daytime sleepiness with stimulants. The goal should be to produce the fullest possible return of normal function for patients at work, at school, at home, and socially. A new recommendation is to control cataplexy, hypnagogic hallucinations, and sleep paralysis, when present and troublesome. The health care provider should consider the benefit-to-risk ratio of medication for an individual patient, the cost of medication, convenience of administration, and the cost of ongoing care including possible laboratory tests when selecting a medication for treatment of narcolepsy.
3.
The following medications are effective treatments for narcolepsy. Comparative safety and efficacy of the stimulant medications are not defined. The rating of the recommendation is based on the grade of evidence for each. See Table 5 for dosages. a. Modafinil is effective for treatment of daytime sleepiness due to narcolepsy {Standard}. [ Table 3 ] This conclusion is based on the favorable benefit-to-risk ratio for modafinil established in three level I, grade A studies with confirmation from additional studies. [20] [21] [22] [23] [24] [25] [26] [27] This is a new recommendation. b.
Amphetamine, methamphetamine, dextroamphetamine, and methylphenidate are effective for treatment of daytime sleepiness due to narcolepsy {Guideline}. [ Table 3 ] These medications are mainstays of narcolepsy treatment. Based on 3 level II, grade B and 4 level V, grade C studies and long clinical practice, they have a long record of efficacy. However, the benefit-to-risk ratio is not well documented, because the published clinical trials include only small numbers of patients. [12] [13] [14] [15] [16] [17] [18] 53 This recommendation is similar to that made previously. c.
Selegiline is an effective treatment for all narcoleptic symptoms {Guideline}. [ Table 3 ] Based on two level II, grade B and one level IV, grade C studies, selegiline is effective, but the cost of the medication is very high, experience with the high doses needed for narcolepsy is limited, and diet-induced hypertension is a danger at effective doses. [28] [29] [30] This is a new recommendation.
d.
Pemoline is effective for treatment of daytime sleepiness in narcolepsy {Option).
[ Table 3 ] Pemoline can produce rare and potentially lethal liver toxicity that may be unpredictable. See the Appendix product alert from Abbott Laboratories for more details and recommendations for ongoing monitoring for liver toxicity. Because of this toxicity, the use of pemoline in patients with narcolepsy is rarely indicated. Based on one level II, grade B study, pemoline may be less potent than amphetamines, 13 but adherence to pemoline therapy may be better than adherence to amphetamines or methylphenidate. 49 This is a modification of a recommendation made previously. In particular, the warning on liver toxic- 4, 2001 ity is emphasized to a greater degree than previously. e.
Tricyclic antidepressants and fluoxetine may be effective treatment for cataplexy, sleep paralysis, and hypnagogic hallucinations {Guideline}.
[ Table 4 ] The recommendation for tricyclic agents is based on one level V, Grade C study, long clinical experience and committee consensus. This is a new recommendation. The recommendation for fluoxetine is based on one level II, grade B and one level V, grade C study. This is a new recommendation. f.
Combinations of long-and short-acting forms of stimulants may be effective for some patients {Option}. Some stimulants have a short (3 to 4 hour) effective period (e.g., methylphenidate).
Others have longer duration of activity and longer onset of action (e.g., modafinil, sustained release amphetamine). By combining stimulants with different activity characteristics, it may be possible to achieve alertness quickly and for longer periods of time and also not produce insomnia as an unwanted side effect. In addition, combinations of stimulants and antidepressants may be of benefit for treatment of sleepiness and REM-related symptoms such as cataplexy. For example, modafinil appears compatible with antidepressant medications, but published evidence is limited. 54 This recommendation is similar to that made previously and is based on committee consensus.
4.
Scheduled naps can be beneficial to combat sleepiness but seldom suffice as primary therapy {Guideline}.
[ Table 2 ] This recommendation is based on two level II, grade B, one level IV, grade C and one level V, grade C studies and long clinical experience. [42] [43] [44] [45] This recommendation is similar to that made previously.
5.
Regular follow-up of patients with narcolepsy is necessary to monitor response to treatment, to respond to potential side effects of medications, and to enhance the patient's adaptation to the disorder {Standard}. a. A patient stabilized on stimulant medication should be seen regularly by a health care provider at least once per year, and preferably once every 6 months, to assess the development of medication side effects, including sleep disturbances, mood changes, and cardiovascular or metabolic abnormalities. This is the same recommendation as made previously and is based on committee consensus. b.
Follow-up is necessary to determine adherence and response to treatment; to monitor for the safety of medications in individual patients; and to assist the patient with occupational and social problems. Adherence to stimulant drug treatment in narcolepsy is impeded by inconvenient dosage, but not by age, educational level, gender, or response to therapy. 49 Of note, many patients with narcolepsy can not be restored to normal levels of daytime alertness, even when adhering to optimum doses of stimulant medications (Table 5 ). Most often, response to therapy can be determined by interview of the patient and associates as well as by self-report questionnaires, such as the Epworth Sleepiness Scale.
Objective measures, such as the MWT or the MSLT, may play a role when occupational or public safety concerns are at issue. This is an expansion of a similar recommendation made previously and is based on committee consensus. c.
Patients with severe sleepiness should be advised to avoid potentially dangerous activities at home and at work, and should not operate a motor vehicle until sleepiness is appropriately controlled by stimulant medications. This recommendation is the same as that previously and is based on one level II, grade B and one level III, grade B study 36, 40 (Table 4 ) and committee consensus. d.
Of the stimulants used to treat narcolepsy, amphetamines, especially at high doses, are the most likely to result in the development of tolerance. This is the same recommendation as previously. Reiteration of the discussion and literature cited in the previous review paper 3 are beyond the scope of the current review and the reader is referred for further information. e.
Patients who fail to respond to adequate doses of stimulant medication should be carefully assessed for other sleep disorders such as insufficient sleep, inadequate sleep hygiene, circadian rhythm disorders, obstructive sleep apnea syndrome, or periodic limb movement disorder, that may contribute to excessive sleepiness. This is essentially the same recommendation as previously and is based on committee consensus. f.
For side effects, dosage ranges, use in pregnancy and by nursing mothers, class of medication and use in narcolepsy, see Table 5 .
The information of Table 5 for dosages. This recommendation is similar to that previously and is based on the considerable experience with use of methylphenidate for treatment of attention deficit disorder. 55 h.
Health care providers should assist the patient with occupational and social accommodation for disabilities due to narcolepsy. The Americans with Disabilities Act provides legal guidance. 56 Patients deserve appropriate help from health care providers to insure that the intent of the law is realized. Because sustained alertness often is difficult to achieve even with optimum treatment, some patients should be advised to avoid potentially dangerous activities, such as driving, climbing, or working in the vicinity of dangerous machinery, which could result in injury to the patient or others. 36, 40, 57 This recommendation is similar to that previously and is based on committee consensus. i.
Polysomnographic reevaluation of patients should be considered if symptoms of sleepiness increase significantly or if specific symptoms develop that suggest new or increased sleep abnormalities as might occur in disorders such as sleep apnea or periodic limb movement disorder. This is the same recommendation as that previously and is based on committee consensus.
Further Research
The preparation of these practice parameters revealed significant weaknesses in the published literature about treatment of narcolepsy. Better studies of diagnostic criteria are needed. Studies which explicitly consider patient preferences about therapeutic objectives, should be undertaken. Further research on selective serotonin reuptake inhibitors (SSRIs), including ones besides fluoxetine available in the United States, should be undertaken. A large comparative clinical trial of amphetamine, methylphenidate, modafinil, and selegiline for treatment of narcolepsy would be of benefit for patient management. Such a study could establish the relative efficacy, side effects, and patient preferences for treatments. A registry should be established to track the outcome of pregnancy in patients who take modafinil and other stimulants that do not have adequate human data. Treatment of cataplexy needs better assessment, and a clinical trial comparing fluoxetine, tricyclic agents, and placebo would be helpful to clinicians. Research about social interventions to improve function of narcoleptic patients at work and home should be a priority. Gamma hydroxybutyrate is being evaluated experimentally and may have a role to play in treating nocturnal awakenings and cataplexy. 58 However, it is not approved by the FDA. Finally, investigation about whether case management of narcolepsy patients might lead to better patient outcomes is needed.
